Bio Path reported $-3.21M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Baxter International USD 426M 36M Sep/2025
Bio Path USD -3.21M 631K Mar/2025
Cipla INR 12.55B 6.4B Dec/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 3.13B 1.17B Dec/2025
Grifols EUR 482.04M 7.04M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024